CFTR and cystic fibrosis: The triple combination of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) was approved in most European countries for people with CF (pwCF) aged ≥2 or 6 years, with at least one F508del, and in the USA it was also approved for pwCF with 177 other responsive CFTR variants [2,9,10].